Beacon is the No. 1 oncology company of Bangladesh & manufactures latest anticancer drugs……..
Tafecta- A potent warrior against Hepatitis B virus
TenofovirAlafenamide is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Due to its enhanced stability in the plasma, TenofovirAlafenamide delivers tenofovir more efficiently to hepatocytes, with approximately 1/10 the dose of TenofovirDisoproxil. In addition, with TenofovirAlafenamide, there is 89% less tenofovir circulating in the plasma, resulting in reduced systemic exposure.
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient…Read More
Registered & Licensed by Regulatory
Authority of Bangladesh
Tafecta is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh. Drug Registration Number: 341-293-10 Inclusion Date: 20-07-2016 Valid up to: 19-07-2021
CORPORATE ADDRESS
Beacon Pharmaceuticals Limited
9/A,Toyenbee Circular Road,
Motijheel,Dhaka-1208, Bangladesh.
Phone: +880-2-57165371-79
Fax: +880 2-57165380
Web: beaconpharma.com.bd
ALTERNATIVE CONTACT 2
Skype ID: masfikur.rahman
WhatsApp: +8801730026182
IMO: +8801730026182
Viber: +8801730026182
Email: [email protected]